CAMTEK ANNOUNCES RESULTS FOR THE THIRD QUARTER OF 2026

Camtek reported record Q3 2026 revenue of $161.3 million, up 28% year over year and 21% sequentially, with GAAP diluted EPS of $0.84 versus a $1.16 loss a year earlier. Management expects approximately $180 million in Q4 revenue and initially forecasts 2027 revenue above $800 million, about 35% growth over 2026, citing its backlog and pipeline. The company generated $71.1 million in Q3 operating cash flow; its CEO linked demand for advanced packaging to AI growth.

Analysis

The key debate is whether the 2027 outlook is already priced as a durable AI-packaging growth curve. If customers convert backlog into tool shipments, operating leverage can support earnings; however, the release does not quantify backlog conversion, customer concentration, or order cancellations, so management’s visibility claim remains a company assertion rather than independent evidence. Margin quality is a watch item: GAAP operating margin eased year over year, while non-GAAP gross margin also slipped, despite rapid revenue growth. That could reflect mix or investment, but sustained erosion would weaken the operating-leverage case.

Do not use the GAAP net-income comparison as evidence of a sudden earnings inflection: the prior-year quarter included a large capital-notes extinguishment loss. Current-period diluted shares also exceed basic shares materially, making diluted EPS the more relevant measure. CAMT’s substantial cash and securities provide resilience, though convertible notes and dilution remain relevant to per-share upside.

Over days, the call’s detail on bookings and conversion may matter more than the headline beat; expectations embedded in the share price are unknown. Over 1–3 months, order cadence, customer capex and gross-margin direction should test the 2027 ramp. Over 6–18 months, advanced-packaging and HBM inspection demand is a structural tailwind, but export controls, Middle East disruption and a slowdown in AI infrastructure spending could defer purchases. KLA, Onto Innovation and Nova are relevant semiconductor-equipment comparables, but product overlap and relative valuation should be verified before making a pair trade.

Key Decisions for Investors

• Avoid chasing solely on the 2027 revenue target. Consider a starter long only if the post-call discussion supports backlog conversion and the stock’s reaction does not imply an already fully priced ramp; no price target is supportable from the supplied data.
• Use the call and upcoming filings to check order intake, backlog cancellation terms and conversion timing, customer concentration, and whether gross margin stabilizes. Treat weaker bookings or further margin compression as reasons to reduce exposure.
• For a 1–3 month catalyst view, monitor customer AI/HBM and advanced-packaging capex commentary alongside CAMT’s next guidance update. A meaningful slowdown in those budgets would falsify the growth thesis before reported revenue necessarily turns.
• Do not infer operational acceleration from the year-over-year GAAP net-income swing. Track diluted EPS and operating income, and compare CAMT with KLA, Onto Innovation and Nova only after confirming product exposure and valuation.